Business Context and Reporting Period
This Form 8-K filing by Arvinas, Inc. reports on events occurring on October 1, 2018. The filing documents corporate governance amendments executed in connection with the closing of the Company's initial public offering (IPO). Arvinas is an emerging growth company incorporated in Delaware.
Financial Metrics
This filing is a current report regarding corporate governance changes and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material changes involve the amendment and restatement of the Company's Certificate of Incorporation and Bylaws effective upon the IPO closing:
- Capital Structure: Authorized common stock increased to 200,000,000 shares; all references to existing preferred stock were eliminated, and 10,000,000 shares of undesignated preferred stock were authorized.
- Board Composition: Established a classified board of directors with three classes serving staggered three-year terms.
- Director Removal: Directors may now be removed only for cause and only with the affirmative vote of at least 75% of stockholder votes.
- Stockholder Rights: Eliminated the ability of stockholders to take action by written consent or to call special meetings.
- Legal Forum: Designated the Court of Chancery of the State of Delaware (or the federal district court for the District of Delaware) as the sole and exclusive forum for specific corporate law claims.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future operations, or specific risk factors beyond the standard legal implications of the governance changes. The primary contingency noted is the effective date of these amendments, which is tied to the closing of the IPO.
Key Facts for Investor Verification
- Verify the final share count and capitalization table post-IPO to confirm the 200,000,000 authorized common shares.
- Review the specific terms of the new undesignated preferred stock authorization (10,000,000 shares) for potential future dilution.
- Confirm the composition of the initial classified board of directors and the staggered term schedule.
- Understand the restrictions on stockholder actions, specifically the inability to call special meetings or act by written consent.